



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

August 14, 2025

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**SUB: Outcome of the Board Meeting held on Thursday, August 14, 2025, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.**

**SYMBOL: AJOONI**

Dear Sir,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company held their meeting on Thursday, 14<sup>th</sup> August 2025 at 10.30 a.m. and concluded at 11.00 a.m. at the Corporate Office of the company situated at House No. 1769, Phase 3B2, Mohali, Punjab. Following transactions were considered and approved:

1. Un-audited Financial Results for the quarter ended June 30, 2025.
2. Limited Review Report from the auditor for the quarter ended June 30, 2024.
3. Re-appointment of Mr. Gursimran Singh (DIN: 02209675) as Whole time Director for a period of five years and fix his remuneration. subject to the approval of shareholders.
4. Any other matter with the permission of the Chair.

Details with respect to re-appointment of Mr. Gursimran Singh (DIN: 02209675) as Whole time Director of the Company as required under Regulation 30(6) read with Para A(7) of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 are provided in Annexure to this letter.

Kindly take same on your records.


**Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited**

**Swati Vijan  
Company Secretary  
FCS13627**

**AJOONI BIOTECH LIMITED**  
**CIN : L85190PB2010PLC040162**

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025 (In Lakhs)**

	PARTICULARS	QUARTER ENDED					Year Ended (Audited)
		30.06.2025	31.03.2025	30.06.2024	Period Ended (UnAudited)	Period Ended (UnAudited)	31.03.2025
					30.06.2025	30.06.2024	
<b>I</b>	<b>Income</b>						
	Revenue from operations	3,126.77	2,927.44	2,565.85	3,126.77	2,565.85	11,469.19
	Other income	64.54	133.64	3.67	64.54	3.67	206.90
	<b>Total income from operations</b>	<b>3,191.31</b>	<b>3,061.08</b>	<b>2,569.52</b>	<b>3,191.31</b>	<b>2,569.52</b>	<b>11,676.09</b>
<b>II</b>	<b>Expenses</b>						
	Cost of Material Consumed	2,564.17	2,259.09	2,248.65	2,564.17	2,248.65	9,715.42
	Change In Inventories	(4.18)	10.87	(1.64)	(4.18)	(1.64)	(12.65)
	Employee benefit expenses	99.21	59.01	57.28	99.21	57.28	275.73
	Finance costs	8.46	5.68	15.02	8.46	15.02	33.43
	Depreciation and amortization expenses	24.83	38.10	22.32	24.83	22.32	109.35
	Payment to NSE						
	Other expenses	396.10	497.14	165.29	396.10	165.29	1,121.88
	<b>Total expenses</b>	<b>3,088.59</b>	<b>2,869.89</b>	<b>2,506.92</b>	<b>3,088.59</b>	<b>2,506.92</b>	<b>11,243.16</b>
<b>III</b>	<b>Profit/(Loss) before exceptional items and tax</b>	<b>102.72</b>	<b>191.19</b>	<b>62.60</b>	<b>102.72</b>	<b>62.60</b>	<b>432.93</b>
<b>IV</b>	<b>Exceptional items</b>						
<b>V</b>	<b>Profit/(Loss) before tax</b>	<b>102.72</b>	<b>191.19</b>	<b>62.60</b>	<b>102.72</b>	<b>62.60</b>	<b>432.93</b>
<b>VI</b>	<b>Tax expenses</b>						
	a) Current tax	22.50	49.24	15.20	22.50	15.20	102.42
	b) Deferred tax	-2.08	12.44	(0.58)	(2.08)	(0.58)	6.70
	b) Mat Credit						
<b>VII</b>	<b>Net Profit/(Loss) for the period/year</b>	<b>78.14</b>	<b>154.39</b>	<b>46.82</b>	<b>78.14</b>	<b>46.82</b>	<b>337.21</b>
<b>VIII</b>	<b>Other comprehensive income (net of tax)</b>						
	loss:		(82.38)				(26.10)
	<b>Total other comprehensive income</b>		<b>(82.38)</b>				<b>(26.10)</b>
<b>IX</b>	<b>Total comprehensive income for the period/year (VII+VIII)</b>	<b>78.14</b>	<b>72.01</b>	<b>46.82</b>	<b>78.14</b>	<b>46.82</b>	<b>311.10</b>




X	Paid-up equity share capital (face value of the share shall be indicated)	3,444.87	3,444.87	3,444.87	3,444.87	3,444.87	3,444.87
XI	Other equity (excluding revaluation reserve)	5,441.16	5,363.02	5,104.74	5,441.16	5,104.74	5,363.02
XII	EPS in Rs. (Face Value of Rs.10/- each)*						
	-Basic	0.02	0.09	0.03	0.02	0.23	0.20
	-Diluted	0.02	0.09	0.03	0.02	0.23	0.20

**Notes:**

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 11.08.2025 after being reviewed by the Audit Committee.
2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited


Jasjot Singh  
Managing Director  
DIN: 01937631



Place : Mohali  
Date : 14/08/2025

Statement of Assets and Liabilities  
For the Quarter ended on 30th June 2025

PARTICULARS	in Rs. (Lakhs)	
	30TH JUNE 2025	31ST MARCH 2025
<b>I. ASSETS</b>		
<b>(1) Non - Current Assets</b>		
a) Property, Plant and Equipment	1,469.76	1,093.31
b) Capital Work In Progress	224.11	29.29
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets	44.94	47.93
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		
(1) Investments	388.16	349.36
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets	0.00	1,506.79
i) Deferred Tax Asset (net)	40.00	37.92
j) Other Non Current Asset	201.52	240.11
<b>(2) Current Assets</b>		
a) Inventories	2,604.07	2,398.69
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	1,876.06	1,621.64
(3) Cash & Cash Equivalent	1,574.89	683.02
(4) Bank Balances other than (iii) above		
(5) Loans	1,333.90	1,330.65
(6) Other Financial Asset		27.37
c) Current Tax Assets (net)		-
d) Other Current Asset	235.11	139.03
<b>TOTAL</b>	<b>9,992.52</b>	<b>9,505.11</b>



**II EQUITY AND LIABILITIES****(1) Equity**

a) Equity Share Capital	3,444.87	3,444.87
b) Other Equity	5,441.16	5,363.02

**(2) Non-Current Liabilities**

a) Financial Liabilities		
(1) Borrowings	536.94	193.97
(2) Trade Payables		
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	22.06	21.13
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-

**(3) Current Liabilities**

a) Financial Liabilities		
(1) Borrowings	0.00	0.00
(2) Trade Payables	391.68	349.52
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	1.44	0.93
c) Other Current Liabilities	131.87	29.25
d) Current tax liabilities (Net)	22.50	102.42

**TOTAL**

9,992.52

9,505.11

Place : Mohali

Date : 14.08.2025

For Ajooni Biotech Limited

Jasjot Singh  
Managing  
Director

DIN: 01937631





**NARINDER KUMAR AND COMPANY**  
**CHARTERED ACCOUNTANTS**

SCO 65-B (1st Floor) City Heart,  
Kharar Chandigarh Road,  
Kharar, SAS Nagar Mohali-140301  
Mobile : 98154 50065  
Email : nkgargca@yahoo.co.in

## Limited Review Report

Ref. No. ....

Dated .....

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 30th June 2025.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY



Chartered Accountants

(NARINDER KUMAR GARG)

PARTNER

M.NO-080287

Date:-14.08.2025

UDIN:- 25080287BMLIUF5744

## Annexure – Brief Profile

Details as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

S.N O.	PARTICULARS	GURSIMRAN SINGH
1.	Type of event	Re-appointment of Mr. Gursimran Singh as Whole Time Director of the Company
2.	Date of Re-appointment & Term of Re-Appointment	With effect from 14 <sup>th</sup> August 2025 for a period of 5 years subject to approval of members in ensuing Annual General Meeting.
3.	Brief Profile	He is qualified as Bachelor of Commerce (B.Com) and Master in Business Administration (MBA). Mr. Gursimran Singh is having more than 15 years of experience in the field of Animal Husbandry, cultivation of crops and supplements required for livestock. He is also working as CEO of Ajooni Biotech Limited since past 8 years of the company. He is an expert and leading entrepreneur in the field of agriculture and has wide expertise as marketing professional and expert knowledge of cultivation of crops/ supplements.
4.	Disclosure of relationships between existing directors and new director	Mr. Gursimran Singh is not related to any of the existing directors on the Board of the Company.
5.	Information as required under NSE Circular - NSE/CML/2018/02 dated June 20, 2018	Mr. Gursimran Singh is not debarred from holding the office of Director by any SEBI order or any other such authority.